Your Health, We Care
Filgotinib has been approved by EMA in Europe for the treatment of adult RA patients. In addition, Filgotinib has been approved by EMA for the treatment of ulcerative colitis (UC), further expanding its indications.
In addition to the completed SELECTION trial, Filgotinib has entered phase 2 research in the treatment of axial spondyloarthritis, psoriatic arthritis, non communicable uveitis, cutaneous lupus, and Sjogren's syndrome, and phase 3 research in the treatment of Crohn's disease (CD).
